Hematopoietic SCT (HSCT) is an important therapeutic modality for patients with malignant and nonmalignant diseases. The number of HSCTs performed has been steadily rising over the past decades as the procedure becomes more available for more patients. This increase in number of transplants is associated with increased healthcare cost, which is not insignificant. The cost of an allogeneic HSCT for the first year ranges from $96 000 to $204 000. 1 Most studies do not factor the cost associated with HLA typing and identifying a donor. [2] [3] [4] HLA typing for HSCT programs is critical for the selection of appropriate recipient-donor pairs. Over the past several years, there have been many improvements in methodologies to enhance the accuracy of HLA typing and help contribute to successful outcomes. New policies and standards have also helped to ensure accuracy throughout the testing process including verification typing on a second sample for all recipients and for the selected donor before transplant.
As more advanced typing methodologies and repeat testing were introduced as standard of practice, our transplant program examined ways to offset these additional costs by streamlining the HLA testing protocols and eliminating unnecessary testing. As family typing accounts for a large part of the HLA typing expense associated with pre-HSCT cost, we implemented a new protocol to reduce the cost associated with related donor HLA typing.
Before 2010, full typing for both Class I and Class II HLA was performed on both recipients and all family donors at our center. If a match was found, Class II high resolution typing was performed and Class I high resolution typing was ordered if family genotype analysis did not confirm two-haplotype matching. In consultation with our HLA laboratory, we established a new quality improvement and cost-saving protocol to perform limited typing on prospective living related donors to 'screen' for possible matched donors. For initial typing of potential donors, we test only for Class I at low resolution. Initial low-resolution typing is done for Class I using microarray technology and reverse sequence-specific oligonucleotide probe methodology. If a matched donor is identified using Class I typing, we then perform high-resolution typing for Class II to complete the typing. Class II high resolution typing is performed using the same microarray technology with high-resolution panel of probes. This method can usually achieve high resolution, with only rare ambiguous combinations being unresolved. In the event that a common or well-documented allele is not resolved, additional resolution is obtained by sequence-specific primers or sequence-based typing. Genotype analysis is performed for all family typing to confirm haplotypes. If haplotype matching does not rule out possible recombination between maternal or paternal haplotypes, highresolution typing for Class I may be done to ensure allelic matching (Figure 1) .
We wanted to evaluate the cost saving associated with the change in practice over a 3-year period from 1 December 2010 to 30 November 2013. The HLA lab maintains a comprehensive database of HLA typing on all recipients and donors tested by the adult and pediatric SCT program. During this time, 1193 potential living related donors were typed for Class I by the transplant program at Vanderbilt University Medical Center and the Monroe Carell Jr Children's Hospital at Vanderbilt. Of these, 342 (28.7%) were found to be a match at Class I and follow-up testing for high-resolution Class II was ordered. This approach resulted in elimination of unnecessary high-resolution Class II typing in 851 potential donors and this resulted in a saving of $170 200 over the 3-year period. In addition to the monetary savings, there is significant unmeasured time saving for the HLA lab technicians.
As advances in HSCT including the use of reduced-intensity transplant allow the procedure to be offered to increasing number of patients, it is essential to examine financial cost of the procedure. With rising healthcare cost in general, it is important to continue to find cost savings that can reduce the cost of HSCT.
Although most published studies do not account for the cost of pre-transplant HLA typing, we have identified a cost-saving approach especially for patients with multiple sibling donors.
